If this message is not displayed correctly, click here.

No 120, January 2018


ENP hosts CME announcements

ENP is now enhanced by a brand new webpage featuring a list of important educational events supported by the Association in 2018. Click on the CME announcements for updated programs and travel grant opportunities for young professionals. Important post-course materials will also be available and accessible to ERA-EDTA members


Submit your abstract for 55th ERA-EDTA Congress in Copenhagen!

1 day to give your abstract the finishing touch – ERA-EDTA abstract submission closes on January 12, 2018, 23.59 CET

Is your abstract ready for the 55th ERA-EDTA Congress? Go ahead, it is worth finishing it! Having your abstract accepted gives you the opportunity to present your work to the nephrology community at the ERA-EDTA Congress, the leading European nephrology congress, and to discuss your findings with other experts in Copenhagen. In addition, all abstracts accepted for presentation (either oral or poster) will appear in NDT.

NDT and CKJ articles

Just published online: read the latest NDT and CKJ articles

How to facilitate iohexol plasma clearance for measuring GFR?

A novel technique by using a dried blood spot (DBS) test might simplify the laborious plasma clearance of iohexol – so far the gold standard method to measure renal function – without loss of accuracy and precision.

In this study published in NDT, the GFR values were assessed by volumetric and non-volumetric DBS and compared with those calculated by the reference technique. Agreement was defined as a TDI (total deviation index) <10%. The non-volumetric DBS showed an unacceptable agreement (TDI=26%). The volumetric method in vitro showed a TDI of 13% and could be ameliorated by using iopamidol as the internal standard (in vitro TDI=9%). This was followed by a clinical validation of the volumetric DBS in 203 patients. The in vivo TDI was 9,5%. Thus, by using this DBS method, 90% of the GFR values lay between −9,5% and + 9,5% compared to the reference method.

SHPT Treatment 2.0

The authors of this review published in CKJ discussed the state-of-the-art treatment of secondary hyperparathyreoidism (sHPT). The classical treatment for sHPT included phosphate binders and active vitamin D compounds, but the latter can become a problem, because they often drive up serum calcium levels. As the authors pointed out, Cinacalcet, a calcimimetic, effectively reduces PTH and improves biochemical control of mineral and bone disorders in chronic kidney patients. In addition, Cinacalcet showed beneficial effects on vascular calcification and bone histology in randomized clinical trials. Nevertheless, the authors believe that Etelcalcetide, a novel second-generation calcimimetic agent, is another step forward. Etelcalcetide has a favourable pharmacokinetic profile, with a longer elimination half-life than Cinacalcet, it showed an even better efficacy in lowering PTH (as well as phosphate, calcium and FGF23). Furthermore, being an i.v. calcimimetic, it reduces pill burden and, thus, improves medication adherence.

ERA-EDTA Registry – looking back at the most recent years of contract

2018 will be the year of contract renewal between ERA-EDTA and AMC in Amsterdam (The Netherlands) on the Registry. We take this opportunity to report on the achievements of the Registry over the last three and a half years in the middle of which Ziad Massy took over as Registry Chairman from Christoph Wanner.

ERA-EDTA: Innovation and Education in Kidney Science and Care.
Web Site

ERA-EDTA Flash is the official ERA-EDTA eNewsletter

Editor-in-Chief: Mustafa Arici
Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters
Via XXIV Maggio, 38
43123 Parma - Italy

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.